GlycoMimetics
ProfileJobs

GlycoMimetics

Suggest Edit
    • Healthbiotechdrug developmentoncologypharma

    GlycoMimetics is a clinical-stage biotechnology company. The Company uses novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. Its products include GMI-1070, a synthetic glycomimetic molecule designed to inhibit selectin types, such as E, P, and L-selectin; and GMI-1051, a small molecular weight compound for the treatment or prevention of infections caused by pseudomonas aeruginosa.

    Market capitalization(2018-04-23)
    $375.7 M
    Type
    Public
    HQ
    Rockville, US
    Founded
    2003
    Size (employees)
    42 (est)
    Website
    glycomimetics.com
    GlycoMimetics was founded in 2003 and is headquartered in Rockville, US
    Report incorrect company information

    Key People/Management at GlycoMimetics

    Brian Hahn

    Brian Hahn

    Chief Financial Officer
    John Baldwin

    John Baldwin

    Director
    Michael Henos

    Michael Henos

    Director
    Franklin H. Top

    Franklin H. Top

    Director
    William Gust

    William Gust

    Director
    M. James Barrett

    M. James Barrett

    Chairman of the Board of Directors

    GlycoMimetics Office Locations

    GlycoMimetics has an office in Rockville
    Rockville, US (HQ)
    9708 Medical Center Dr
    Show all (1)
    Report incorrect company information

    GlycoMimetics Financials and Metrics

    GlycoMimetics Financials

    GlycoMimetics's revenue was reported to be $18.50 k in FY, 2016 which is a 99.9% decrease from the previous period.
    USD

    EBIT (FY, 2017)

    		(33.9 m)

    Market capitalization (23-Apr-2018)

    		375.7 m

    Cash (31-Dec-2017)

    		123.9 m
    GlycoMimetics's current market capitalization is $375.7 m.
    Annual
    USDFY, 2014FY, 2015FY, 2016

    Revenue

    		15 m20.1 m18.5 k

    Revenue growth, %

    		34%(100%)

    EBIT

    		(11.1 m)(12.8 m)

    EBIT margin, %

    		(74%)(64%)
    Quarterly
    USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017

    Net Income

    		2.9 m(3.7 m)(7.1 m)3.3 m(3.9 m)(7.6 m)(15.6 m)(23.5 m)(7.9 m)(24 m)
    show all
    Annual
    USDFY, 2014FY, 2015FY, 2016FY, 2017

    Cash

    		55.2 m46.8 m40 m123.9 m

    Accounts Receivable

    		13.6 m

    Inventories

    		916.2 k441.8 k478.5 k

    Current Assets

    		56.1 m47.2 m40.5 m127.2 m
    Quarterly
    USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

    Cash

    		57 m66.2 m61.4 m46.6 m40.2 m53.8 m38.8 m53.1 m45.3 m34.6 m119.1 m112.9 m

    Accounts Receivable

    		20 m

    Inventories

    		1 m

    Current Assets

    		57.7 m67.1 m61.9 m47.3 m60.8 m54.5 m39.5 m54.5 m46.5 m35.3 m119.7 m113.9 m
    show all
    Annual
    USDFY, 2014FY, 2015FY, 2016FY, 2017

    Net Income

    		(11.1 m)(12.8 m)(31.8 m)(33.3 m)

    Depreciation and Amortization

    		158.7 k191.5 k190.5 k263.5 k

    Inventories

    		1.7 m474.4 k(36.7 k)

    Accounts Payable

    		(270.9 k)(309.8 k)1 m1.1 m
    Quarterly
    USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

    Net Income

    		(5.1 m)2.9 m(3.7 m)(7.1 m)3.3 m(3.9 m)(7.6 m)(15.6 m)(23.5 m)(7.9 m)(16.1 m)(24 m)

    Depreciation and Amortization

    		34.6 k73.5 k114.3 k44.2 k90.5 k142.4 k47.2 k93.9 k139.7 k54.3 k123.9 k

    Inventories

    		1 m

    Accounts Payable

    		652.1 k(672.7 k)(561.2 k)299.5 k222.5 k(240.9 k)1 m816.9 k682.5 k(1.1 m)(990.1 k)1.6 m
    show all
    USDY, 2017

    Financial Leverage

    		1.1 x
    Show all financial metrics
    Report incorrect company information

    Competitors

    Agenus
    Health - Public
    Ionis Pharmaceuticals
    Health - Public
    Repligen
    Health - Public
    AcelRx Pharmaceuticals
    Health - Public
    Compare competitors

    GlycoMimetics News and Updates

    April 04, 2018

    GlycoMimetics: Buy This Dip

    March 09, 2018

    New Detailed Study on Anemia Drugs Market by Leading Key Players: GlycoMimetics, Mast Therapeutics, Fibrogen

    Anemia Drugs Market Latest Developments by Type, by End-Users/Application, by Region - Forecast and Business Outlook Posted via Industry Today. Follow us on Twitter @IndustryToday
    Report incorrect company information
    Download PDF